Botulinum toxin A topical - Revance Therapeutics
Alternative Names: RT 001 - Revance; RT-001Latest Information Update: 24 Mar 2025
At a glance
- Originator Revance Therapeutics
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Facial wrinkles; Hyperhidrosis; Migraine; Neuropathic pain
Most Recent Events
- 23 Feb 2023 Discontinued - Phase-II for Migraine in USA (Topical)
- 23 Feb 2023 Discontinued - Preclinical for Neuropathic pain in USA (Topical)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Topical)